JP2023500033A5 - - Google Patents
Info
- Publication number
- JP2023500033A5 JP2023500033A5 JP2022521196A JP2022521196A JP2023500033A5 JP 2023500033 A5 JP2023500033 A5 JP 2023500033A5 JP 2022521196 A JP2022521196 A JP 2022521196A JP 2022521196 A JP2022521196 A JP 2022521196A JP 2023500033 A5 JP2023500033 A5 JP 2023500033A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- calreticulin
- eye disease
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201914516A GB201914516D0 (en) | 2019-10-08 | 2019-10-08 | Treatment of eye disease |
| GB1914516.8 | 2019-10-08 | ||
| PCT/EP2020/078173 WO2021069523A1 (en) | 2019-10-08 | 2020-10-07 | Calreticulin for treating or preventing an angiogenic eye disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500033A JP2023500033A (ja) | 2023-01-04 |
| JP2023500033A5 true JP2023500033A5 (OSRAM) | 2023-11-29 |
Family
ID=68541456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521196A Pending JP2023500033A (ja) | 2019-10-08 | 2020-10-07 | 血管新生性眼疾患を治療又は予防するためのカルレティキュリン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220370554A1 (OSRAM) |
| EP (1) | EP4041280A1 (OSRAM) |
| JP (1) | JP2023500033A (OSRAM) |
| KR (1) | KR20220079917A (OSRAM) |
| GB (1) | GB201914516D0 (OSRAM) |
| WO (1) | WO2021069523A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114699506A (zh) * | 2021-12-30 | 2022-07-05 | 北京百华百汇生物科技有限公司 | 重组钙网蛋白在生发、育发、保护毛发或防脱发中的用途和相关产品 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867180B1 (en) | 1998-10-06 | 2005-03-15 | The United States Of America As Represented By The Department Of Health And Human Services | Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth |
| AU6291799A (en) | 1998-10-06 | 2000-04-26 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth |
| US9254310B2 (en) * | 2010-06-17 | 2016-02-09 | New York University | Therapeutic and cosmetic uses and applications of calreticulin |
| TWI445543B (zh) | 2012-05-03 | 2014-07-21 | Univ Nat Sun Yat Sen | 一種用以治療眼部脈絡膜血管新生之醫藥組合物 |
| EP2872644B1 (en) | 2012-07-12 | 2017-07-12 | UAB Baltymas | Generation of native recombinant secreted human endoplasmic reticulum chaperones by using their native signal sequences in yeast expression systems |
| GB201401453D0 (en) * | 2014-01-28 | 2014-03-12 | Univ Birmingham | Transmucosal and transepithelial drug delivery system |
-
2019
- 2019-10-08 GB GB201914516A patent/GB201914516D0/en not_active Ceased
-
2020
- 2020-10-07 JP JP2022521196A patent/JP2023500033A/ja active Pending
- 2020-10-07 US US17/767,232 patent/US20220370554A1/en active Pending
- 2020-10-07 KR KR1020227015264A patent/KR20220079917A/ko active Pending
- 2020-10-07 EP EP20789562.4A patent/EP4041280A1/en active Pending
- 2020-10-07 WO PCT/EP2020/078173 patent/WO2021069523A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10442852B2 (en) | Methods and compositions for treatment of symptoms associated with intracranial hemorrhage | |
| US7655627B2 (en) | Muteins of fibroblast growth factor 21 | |
| Jiang et al. | Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. | |
| US9044436B2 (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| JP5451533B2 (ja) | 薬理学的硝子体融解 | |
| US7582607B2 (en) | Muteins of fibroblast growth factor 21 | |
| JP6677827B2 (ja) | 眼科用医薬組成物 | |
| TWI272948B (en) | HSA-free stabilized interferon liquid formulations | |
| MX383971B (es) | Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan. | |
| US20240024421A1 (en) | Recombinant modified fibroblast growth factors and therapeutic uses thereof | |
| FI4027983T3 (fi) | Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla | |
| JP2021522180A5 (OSRAM) | ||
| KR20200078425A (ko) | 재조합 변형된 섬유아세포 성장 인자 및 이의 치료적 용도 | |
| KR102789464B1 (ko) | 란피르나제 및/또는 암피나제를 사용하는 바이러스성 결막염의 치료 | |
| JP2023135646A5 (OSRAM) | ||
| WO2022183418A1 (zh) | 抗vegf抗体制剂 | |
| US20240199752A1 (en) | Treatment of ophthalmic diseases | |
| CN102336812B (zh) | 一种具有抑制血管生成活性的多肽 | |
| KR101467841B1 (ko) | 트롬빈 유래 펩타이드를 포함하는 망막증 또는 녹내장 치료용 조성물 | |
| WO2023019218A1 (en) | Modified fibroblast growth factors for treating fibrotic diseases | |
| US20240189448A1 (en) | Dna structure for treating ocular pathologies | |
| US20220370554A1 (en) | Calreticulin for Treating or Preventing an Angiogenic Eye Disease | |
| CN104371003A (zh) | 预防和治疗炎症的小分子多肽及其应用 | |
| JP2026503094A (ja) | 安定化エングレイルドタンパク質水性組成物 | |
| US20220023389A1 (en) | Vasodilators for use in the treatment of a retinal ischemic disorder |